Article thumbnail

Efficacy of Alternative Antiandrogen Therapy for Prostate Cancer That Relapsed after Initial Maximum Androgen Blockade

By Joon Il Choi, Yun Beom Kim, Seung Ok Yang, Jeong Kee Lee and Tae Young Jung
Topics: Original Article
Publisher: The Korean Urological Association
OAI identifier: oai:pubmedcentral.nih.gov:3151633
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. Alternative antiandrogen therapy in patients with castration-resistant prostate cancer: a single-center experience.
  2. Alternative antiandrogens to treat prostate cancer relapse after initial hormone therapy.
  3. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
  4. An update on androgen deprivation therapy for prostate cancer.
  5. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
  6. Bilateral adrenalectomy in prostatic cancer; clinical features and urinary excretion of 17-ketosteroids and estrogen.
  7. Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.
  8. Combined androgen blockade with nonsteroidal antiandrogens for advanced prostate cancer: a systematic review.
  9. Current treatment strategies for castration-resistant prostate cancer.
  10. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.
  11. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
  12. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
  13. Effects of flutamide as a second-line agent for maximum androgen blockade of hormone refractory prostate cancer.
  14. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.
  15. Estramustine phosphate based chemotherapy for hormone refractory prostate cancer.
  16. (2005). Maximum androgen blockade: a clinical Update. Rev Urol
  17. Novel secondary hormonal therapy in advanced prostate cancer: an update.
  18. Predictive variables of the progression to androgen independent prostate cancer after combined androgen blockade.
  19. (1993). Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome.
  20. Secondary hormonal therapy for advanced prostate cancer.
  21. Secondary hormonal therapy for prostate cancer: what lies on the horizon?
  22. Studies on prostate cancer, I. the effect of castration, of estrogen and of androgen injection on serum phosphatase in metastatic carcinoma of the prostate.
  23. Tannock IF. The changing face of hormonal therapy for prostate cancer.
  24. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.